22 August 2022 | Features
Bioprocessing technologies from Repligen are designed to deliver configurable options for your end-to-end modern bioprocessing needs
Repligen, a leader in the development and production of materials used in the manufacture of biological drugs, has opened a new customer experience centre in Bengaluru. With this new facility in India, Repligen is inspiring advances in bioprocessing for the customers it serves; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) across the country.
Whether the work is in fed-batch, hybrid continuous or full continuous mode, or working with therapeutic proteins, gene therapy or vaccines, leading edge workflow solutions from Repligen will streamline processes and cut manufacturing costs.
Bioprocessing technologies from Repligen are designed to deliver configurable options for your end-to-end modern bioprocessing needs. Through this customer experience centre, the company also intends to focus on biopharmaceutical process efficiency and effectiveness through innovation in single-use technologies in India.
“The Repligen journey in India began in 2010 due to the demand of the Indian bioprocessing market. To grow our footprint in India in terms of direct sales and sales support, we have created this space where our customers can come to us and learn about new processes. For instance, single-use chromatography systems from Repligen solve the yield, shear, and separation challenges of traditional systems, through expert engineering and technological innovation of both hardware and flow path,” said Stephen K. Tingley, Vice President, Sales, Repligen
A major gap in bioprocessing is the lack of skilled and trained manpower. As a result, the companies turn to experts at Repligen to better understand the functioning of technologies such as tangential flow filtration (TFF), alternating tangential flow (ATF). So, the new customer experience centre will be addressing this challenge by training customers and updating them with the latest technologies.
According to Vijay David, Managing Director, India & Sales Director- Asia, Repligen, “During the phase I activity at the new customer experience centre, we will be training our customers with the latest technologies, followed by the next phase in which we will slowly start taking in customer projects and developing applications for them.”
With these goals in mind, the company plans to invest more into scientific and technical resources in India for sustainable growth in the next five years.
“I am very happy that Repligen has opened this new costumer experience centre here in India. Serum Institute of India has been working with Repligen since many years. Particularly, their team was there to help during the COVID-19 times. The biopharma, pharma, biotech industry needs the support of such technology-based companies in terms of using different chromatography and filtration systems. Companies like Repligen provide the much-needed backbone to us to develop products such as vaccines etc. And now the use of single-use technologies is the need of the hour which is being provided by Repligen.”
Dr Suresh Beri, Additional Director, Polysaccharide Conjugate Vaccine Division, Serum Institute of India